For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 18 results
Author Title [ Type(Desc)] Year
Filters: Author is Sanders, Rogier W  [Clear All Filters]
Journal Article
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al..  2018.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng. 115(4):885-899.
van Montfort T, Melchers M, Isik G, Menis S, Huang P-S, Matthews K, Michael E, Berkhout B, Schief WR, Moore JP et al..  2011.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.. J Biol Chem. 286(25):22250-61.
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
Banerjee K, Andjelic S, Klasse PJohan, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.  2009.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.. Virology. 389(1-2):108-21.
Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC et al..  2018.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.. PLoS Pathog. 14(2):e1006913.
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al..  2015.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.
Klasse PJohan, Sanders RW, Cerutti A, Moore JP.  2012.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. 28(1):1-15.
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.  2010.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. AIDS Res Hum Retroviruses. 26(4):445-58.
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al..  2015.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.
Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K et al..  2010.  Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.. Virology. 401(2):236-47.
Berro R, Klasse PJohan, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP.  2011.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.. J Virol. 85(16):8227-40.
Sanders RW, Moore JP.  2017.  Native-like Env trimers as a platform for HIV-1 vaccine design.. Immunol Rev. 275(1):161-182.
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M et al..  2011.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.. Science. 334(6059):1097-103.
Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, Bontjer I, van de Sandt C, David K, Berkhout B, Moore JP et al..  2011.  A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.. Retrovirology. 8:48.
Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW.  2010.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.. J Biol Chem. 285(47):36456-70.
Melchers M, Bontjer I, Tong T, P Y Chung N, Klasse PJohan, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC et al..  2012.  Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.. J Virol. 86(5):2488-500.
Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YKenneth, Depetris R, Marozsan AJ, Sanders RW et al..  2011.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.. Proc Natl Acad Sci U S A. 108(28):11440-5.
Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP.  2009.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.. PLoS Pathog. 5(8):e1000548.